These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 23884270

  • 41. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.
    Olson SR, Lu E, Sulpizio E, Shatzel JJ, Rueda JF, DeLoughery TG.
    Am J Nephrol; 2018; 48(2):96-107. PubMed ID: 30110670
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
    Fakhouri F, Frémeaux-Bacchi V, Loirat C.
    Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. ATYPICAL HEMOLYTIC UREMIC SYNDROME IN AN ADULT SUCCESSFULLY TREATED WITH ECULIZUMAB.
    Chaudoir C, Ong MG, Gu X, Veillon D, Cotelingam J.
    J La State Med Soc; 2016 Sep; 168(1):12-5. PubMed ID: 26986861
    [Abstract] [Full Text] [Related]

  • 49. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S.
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count.
    Dorresteijn EM, van de Kar NC, Cransberg K.
    Pediatr Nephrol; 2012 Jul; 27(7):1193-5. PubMed ID: 22399074
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab?
    Saland J.
    Pediatr Nephrol; 2014 Mar; 29(3):329-32. PubMed ID: 24362724
    [Abstract] [Full Text] [Related]

  • 55. Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection -is plasma exchange or eculizumab use necessary?
    Saida K, Ogura M, Kano Y, Ishimori S, Yoshikawa T, Nagata H, Sato M, Kamei K, Ishikura K.
    BMC Nephrol; 2018 Dec 17; 19(1):365. PubMed ID: 30558570
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B.
    Gilbert RD, Fowler DJ, Angus E, Hardy SA, Stanley L, Goodship TH.
    Pediatr Nephrol; 2013 Aug 17; 28(8):1315-8. PubMed ID: 23624872
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Hemolytic uremic syndrome associated with Bordetella pertussis infection in a 2-month-old infant carrying a pathogenic variant in complement factor H.
    Madden I, Roumenina LT, Langlois-Meurinne H, Guichoux J, Llanas B, Frémeaux-Bacchi V, Harambat J, Godron-Dubrasquet A.
    Pediatr Nephrol; 2019 Mar 17; 34(3):533-537. PubMed ID: 30560448
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.